Thus, Debarri et al. have reported the study of 31 AML patients with NPM1 mutant AMLs harboring NPM1 mutations in association with IDH1/IDH2 or DNMT3A mutations: The monitoring of IDH1/IDH2 mutations, but not DNMT3A mutations, allowed detecting the presence of leukemic disease and thus predicting relapse in the majority of patients [114]. This evidence concerns the gene IDH2 and acute myeloid leukemia.